<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">iBio, Inc.</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:3169c850-a6de-45df-9472-be8fa536947a;id=9349</id>
  <rights
    type="text">Copyright 2024, iBio, Inc.</rights>
  <updated>2024-11-12T21:05:00Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/HCx5c2vDCkzMVhPLwLqfjQ==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/HCx5c2vDCkzMVhPLwLqfjQ==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/11/12/2979659/0/en/iBio-Reports-Fiscal-First-Quarter-2025-Financial-Results.html</id>
    <title
      type="text">iBio Reports Fiscal First Quarter 2025 Financial Results</title>
    <published>2024-11-12T21:05:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/11/12/2979659/0/en/iBio-Reports-Fiscal-First-Quarter-2025-Financial-Results.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[Advanced myostatin program with dosing underway in non-human primate study <pre>Advanced myostatin program with dosing underway in non-human primate study</pre>]]></content>
    <dc:identifier>2979659</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 12 Nov 2024 21:05 GMT</dc:modified>
    <dc:subject>Earnings Releases and Operating Results</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/10/10/2961263/0/en/iBio-and-AstralBio-Provide-Update-on-Myostatin-Program-for-Obesity.html</id>
    <title
      type="text">iBio and AstralBio Provide Update on Myostatin Program for Obesity</title>
    <published>2024-10-10T12:00:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/10/10/2961263/0/en/iBio-and-AstralBio-Provide-Update-on-Myostatin-Program-for-Obesity.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[Lead molecule identified with potential extended half-life and subcutaneous dosing <pre>Lead molecule identified with potential extended half-life and subcutaneous dosing</pre>]]></content>
    <dc:identifier>2961263</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Thu, 10 Oct 2024 12:00 GMT</dc:modified>
    <dc:subject>Health</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/09/20/2949885/0/en/iBio-Reports-Fiscal-Year-2024-Financial-Results-and-Provides-Corporate-Update.html</id>
    <title
      type="text">iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update</title>
    <published>2024-09-20T20:05:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/09/20/2949885/0/en/iBio-Reports-Fiscal-Year-2024-Financial-Results-and-Provides-Corporate-Update.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SAN DIEGO, Sept.  20, 2024  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8cIrZccEbBmHzRk14U1ikNb0tQzMMFe5aBcKWkFnaV-tEqm7ghUzdnYJlBMsRuObBkLNuBdHMvbbbPVYxQlCOg==" rel="nofollow" target="_blank" title="iBio, Inc.">iBio, Inc.</a> (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.<br></p>]]></content>
    <dc:identifier>2949885</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Fri, 20 Sep 2024 20:05 GMT</dc:modified>
    <dc:subject>Earnings Releases and Operating Results</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/09/03/2939497/0/en/iBio-to-Participate-in-Upcoming-Investor-Conferences.html</id>
    <title
      type="text">iBio to Participate in Upcoming Investor Conferences</title>
    <published>2024-09-03T11:00:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/09/03/2939497/0/en/iBio-to-Participate-in-Upcoming-Investor-Conferences.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SAN DIEGO, Sept.  03, 2024  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences.<br></p>]]></content>
    <dc:identifier>2939497</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 03 Sep 2024 11:00 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/08/12/2928796/0/en/iBio-Expands-Executive-Leadership-Team-with-Appointment-of-Kristi-Sarno-as-Senior-Vice-President-of-Business-Development.html</id>
    <title
      type="text">iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development</title>
    <published>2024-08-12T20:30:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/08/12/2928796/0/en/iBio-Expands-Executive-Leadership-Team-with-Appointment-of-Kristi-Sarno-as-Senior-Vice-President-of-Business-Development.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[Life sciences industry veteran to lead strategic alliances for iBio’s machine learning platform for antibody discovery and pipeline of cardiometabolic targets <pre>Life sciences industry veteran to lead strategic alliances for iBio’s machine learning platform for antibody discovery and pipeline of cardiometabolic targets</pre>]]></content>
    <dc:identifier>2928796</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 12 Aug 2024 20:30 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
    <dc:subject>Changes in share capital and votes</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/06/03/2892093/0/en/iBio-Closes-Sale-of-Manufacturing-Facility-in-Texas.html</id>
    <title
      type="text">iBio Closes Sale of Manufacturing Facility in Texas</title>
    <published>2024-06-03T11:00:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/06/03/2892093/0/en/iBio-Closes-Sale-of-Manufacturing-Facility-in-Texas.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>– </em><em>The sale of the facility eliminates $13.2M of secured debt –</em></p>]]></content>
    <dc:identifier>2892093</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 03 Jun 2024 11:00 GMT</dc:modified>
    <dc:subject>Business Contracts</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/05/13/2880862/0/en/iBio-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html</id>
    <title
      type="text">iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update</title>
    <published>2024-05-13T20:05:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/05/13/2880862/0/en/iBio-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, May  13, 2024  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.</p>]]></content>
    <dc:identifier>2880862</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 13 May 2024 20:05 GMT</dc:modified>
    <dc:subject>Earnings Releases and Operating Results</dc:subject>
    <dc:keyword>Earnings</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/03/27/2853011/0/en/iBio-and-AstralBio-Announce-Transformative-AI-drug-discovery-Collaboration-to-Rapidly-Develop-Novel-Antibodies-for-Obesity-and-Cardiometabolic-Diseases.html</id>
    <title
      type="text">iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases</title>
    <published>2024-03-27T11:00:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/03/27/2853011/0/en/iBio-and-AstralBio-Announce-Transformative-AI-drug-discovery-Collaboration-to-Rapidly-Develop-Novel-Antibodies-for-Obesity-and-Cardiometabolic-Diseases.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –</em><br></p>]]></content>
    <dc:identifier>2853011</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Wed, 27 Mar 2024 11:00 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
    <dc:subject>Partnerships</dc:subject>
    <dc:subject>Conference Calls/ Webcasts</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/03/26/2852850/0/en/iBio-Announces-15-0-Million-Private-Placement.html</id>
    <title
      type="text">iBio Announces $15.0 Million Private Placement</title>
    <published>2024-03-26T23:35:11Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/03/26/2852850/0/en/iBio-Announces-15-0-Million-Private-Placement.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>– Purchase price of $2.85 represents a premium of 148+% to last close –</em><br></p>]]></content>
    <dc:identifier>2852850</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 26 Mar 2024 23:35 GMT</dc:modified>
    <dc:subject>Financing Agreements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/02/26/2835048/0/en/iBio-Announces-Sale-of-Preclinical-PD-1-Agonist-Antibody-Program-to-Otsuka.html</id>
    <title
      type="text">iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka</title>
    <published>2024-02-26T12:45:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/02/26/2835048/0/en/iBio-Announces-Sale-of-Preclinical-PD-1-Agonist-Antibody-Program-to-Otsuka.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>– Deal includes $1 million upfront and potential future milestone payments </em>–<br></p>]]></content>
    <dc:identifier>2835048</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 26 Feb 2024 12:45 GMT</dc:modified>
    <dc:subject>Health</dc:subject>
    <dc:subject>Mergers and Acquisitions</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2024/01/16/2809865/0/en/iBio-Announces-Participation-in-23rd-Annual-PepTalk-Conference.html</id>
    <title
      type="text">iBio Announces Participation in 23rd Annual PepTalk Conference</title>
    <published>2024-01-16T13:15:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2024/01/16/2809865/0/en/iBio-Announces-Participation-in-23rd-Annual-PepTalk-Conference.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - <pre>- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -</pre>]]></content>
    <dc:identifier>2809865</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 16 Jan 2024 13:15 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
    <dc:subject>Conference Calls/ Webcasts</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/12/26/2801051/0/en/iBio-Amends-and-Extends-Maturity-of-Credit-Agreement.html</id>
    <title
      type="text">iBio Amends and Extends Maturity of Credit Agreement</title>
    <published>2023-12-26T12:15:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/12/26/2801051/0/en/iBio-Amends-and-Extends-Maturity-of-Credit-Agreement.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>– Extends maturity date to March 29, 2024 –</em><br></p>]]></content>
    <dc:identifier>2801051</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 26 Dec 2023 12:15 GMT</dc:modified>
    <dc:subject>Financing Agreements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/12/05/2790859/0/en/iBio-Inc-Announces-Pricing-of-4-5-Million-Public-Offering.html</id>
    <title
      type="text">iBio, Inc. Announces Pricing of $4.5 Million Public Offering</title>
    <published>2023-12-05T13:00:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/12/05/2790859/0/en/iBio-Inc-Announces-Pricing-of-4-5-Million-Public-Offering.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, Dec.  05, 2023  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The Series C Warrants to purchase up to an aggregate of 2,250,000 shares of common stock and Series D Warrants to purchase up to an aggregate of 2,250,000 shares of common stock will have an exercise price of $2.00 per share, will be exercisable immediately following the date of issuance and will expire two years and five years from the original issuance date, respectively.<br></p>]]></content>
    <dc:identifier>2790859</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 05 Dec 2023 13:01 GMT</dc:modified>
    <dc:subject>Stock Market News</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/11/27/2786548/0/en/iBio-Announces-Reverse-Stock-Split.html</id>
    <title
      type="text">iBio Announces Reverse Stock Split</title>
    <published>2023-11-27T22:20:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/11/27/2786548/0/en/iBio-Announces-Reverse-Stock-Split.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, Nov.  27, 2023  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708.   <br></p>]]></content>
    <dc:identifier>2786548</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 27 Nov 2023 22:20 GMT</dc:modified>
    <dc:subject>Changes in share capital and votes</dc:subject>
    <dc:subject>Changes in company's own shares</dc:subject>
    <dc:subject>Major shareholder announcements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/11/01/2771164/0/en/iBio-Further-Expands-Tech-Stack-with-ShieldTx-Enhances-Immuno-Oncology-Development-Pipeline-with-Conditionally-Activated-MUC16xCD3-Bispecific.html</id>
    <title
      type="text">iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific</title>
    <published>2023-11-01T12:24:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/11/01/2771164/0/en/iBio-Further-Expands-Tech-Stack-with-ShieldTx-Enhances-Immuno-Oncology-Development-Pipeline-with-Conditionally-Activated-MUC16xCD3-Bispecific.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -</em><br></p>]]></content>
    <dc:identifier>2771164</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Wed, 01 Nov 2023 12:24 GMT</dc:modified>
    <dc:subject>Health</dc:subject>
    <dc:subject>Product / Services Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/10/10/2757444/0/en/iBio-to-Highlight-Technology-for-Advancing-Discovery-of-Bispecifics-at-Festival-of-Biologics.html</id>
    <title
      type="text">iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics</title>
    <published>2023-10-10T12:00:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/10/10/2757444/0/en/iBio-to-Highlight-Technology-for-Advancing-Discovery-of-Bispecifics-at-Festival-of-Biologics.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries -</em><br></p>]]></content>
    <dc:identifier>2757444</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Tue, 10 Oct 2023 12:02 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
    <dc:subject>Health</dc:subject>
    <dc:subject>Clinical Study</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/10/02/2752591/0/en/iBio-Explains-Recent-Filing-of-Registration-Statement.html</id>
    <title
      type="text">iBio Explains Recent Filing of Registration Statement</title>
    <published>2023-10-02T10:45:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/10/02/2752591/0/en/iBio-Explains-Recent-Filing-of-Registration-Statement.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[–  No new securities are being registered under the Post-Effective Amendment – <pre>–  No new securities are being registered under the Post-Effective Amendment –</pre>]]></content>
    <dc:identifier>2752591</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 02 Oct 2023 10:45 GMT</dc:modified>
    <dc:subject>Company Regulatory Filings</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/09/27/2750762/0/en/iBio-Announces-Filing-of-2023-Annual-Report-on-SEC-Form-10-K.html</id>
    <title
      type="text">iBio Announces Filing of 2023 Annual Report on SEC Form 10-K</title>
    <published>2023-09-27T20:19:28Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/09/27/2750762/0/en/iBio-Announces-Filing-of-2023-Annual-Report-on-SEC-Form-10-K.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, Sept.  27, 2023  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023.<br></p>]]></content>
    <dc:identifier>2750762</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Wed, 27 Sep 2023 20:20 GMT</dc:modified>
    <dc:subject>Company Regulatory Filings</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/09/21/2747658/0/en/iBio-Announces-Amendment-to-Credit-Agreement-with-Woodforest.html</id>
    <title
      type="text">iBio Announces Amendment to Credit Agreement with Woodforest</title>
    <published>2023-09-21T20:05:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/09/21/2747658/0/en/iBio-Announces-Amendment-to-Credit-Agreement-with-Woodforest.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center">– Extends maturity date to December 31, 2023 –</p>]]></content>
    <dc:identifier>2747658</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Sep 2023 22:58 GMT</dc:modified>
    <dc:subject>Financing Agreements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/08/14/2725022/0/en/iBio-Reports-Triple-Milestone-In-Vivo-Proof-of-Concept-for-Three-Programs-a-Transformative-Step-in-Advancing-its-Immuno-Oncology-Pre-Clinical-Pipeline-Towards-Clinical-Development.html</id>
    <title
      type="text">iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development</title>
    <published>2023-08-14T20:15:00Z</published>
    <updated>2024-11-13T20:01:15Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/08/14/2725022/0/en/iBio-Reports-Triple-Milestone-In-Vivo-Proof-of-Concept-for-Three-Programs-a-Transformative-Step-in-Advancing-its-Immuno-Oncology-Pre-Clinical-Pipeline-Towards-Clinical-Development.html" />
    <category
      term="NYSE:IBIO"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US45107K1025"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="center"><em>– </em><em>AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets </em><em>–</em><br></p>]]></content>
    <dc:identifier>2725022</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>iBio, Inc.</dc:contributor>
    <dc:modified>Mon, 14 Aug 2023 20:15 GMT</dc:modified>
    <dc:subject>Health</dc:subject>
    <dc:subject>Product / Services Announcement</dc:subject>
  </entry>
</feed>